Who
Cassie Jung
Chief Operating Officer
Company insider
Files Form 4 as: Chief Operating Officer, Aquestive Therapeutics.
In numbers
- Trades disclosed
- 37
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $1.2M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 9 Mar 2023
- Last trade
- 3 Sep 2026
- Last filed
- 8 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Sep 2026filed 8 Sep 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code X | $4,4044,587 at $0.96 | filing |
| 3 Sep 2026filed 8 Sep 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code X | —4,587 at $0.00 | filing |
| 3 Sep 2026filed 8 Sep 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code X | —4,587 at $0.00 | filing |
| 3 Sep 2026filed 8 Sep 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code X | $4,4044,587 at $0.96 | filing |
| 5 May 2026filed 7 May 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code F | $304K72,734 at $4.18 | filing |
| 5 May 2026filed 7 May 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code F | $304K72,734 at $4.18 | filing |
| 10 Mar 2026filed 11 Mar 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $191K45,791 at $4.17 | filing |
| 10 Mar 2026filed 11 Mar 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $191K45,791 at $4.17 | filing |
| 9 Mar 2026filed 11 Mar 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —42,500 at $0.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —42,500 at $0.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 15 Oct 2025filed 17 Oct 2025 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 15 Oct 2025filed 17 Oct 2025 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code M | $78K25,000 at $3.10 | filing |
| 15 Oct 2025filed 17 Oct 2025 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $474K67,575 at $7.01 | filing |
| 4 Sep 2025filed 8 Sep 2025 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 4 Sep 2025filed 8 Sep 2025 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 4 Sep 2025filed 8 Sep 2025 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code M | $79K25,000 at $3.15 | filing |
| 4 Sep 2025filed 8 Sep 2025 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code M | $18K25,000 at $0.71 | filing |
| 4 Sep 2025filed 8 Sep 2025 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $311K62,180 at $5.00 | filing |
News
Aquestive Therapeutics Wins FDA Acceptance Of Anaphylm NDA ResubmissionAQST · rttnews.com · 15 Oct 2026Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal FilmAQST · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name Cassie Jung; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.